Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
NCT02058901
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
101
Enrollment
OTHER
Sponsor class
Conditions
Solid Tumors
Interventions
DRUG:
Sunitinib
Sponsor
Amsterdam UMC, location VUmc